Today's Research: ZIOPHARM Oncology Inc., Antares Pharma Inc., Chelsea Therapeutics Intl. Ltd, and Accuray Inc.
Today's Research: ZIOPHARM Oncology Inc., Antares Pharma Inc., Chelsea Therapeutics Intl. Ltd, and Accuray Inc. PR Newswire LONDON, November 22, 2013 LONDON, November 22, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. The U.S. equity market edged higher on Thursday, November 21, 2013. The S&P 500 ended the day at 1,795.85, up 0.81%; the Dow Jones Industrial Average closed at 16,009.99, up 0.69%; and the NASDAQ Composite finished at 3,969.16, up 1.22%. Shares in the healthcare sector ended on a higher note, tracking gains in the broader market. The major movers in the sector included ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), Antares Pharma Inc. (NASDAQ: ATRS), Chelsea Therapeutics International Ltd (NASDAQ: CHTP), and Accuray Inc. (NASDAQ: ARAY). AAAResearchReports.com has completed their technical analysis on ZIOP, ATRS, CHTP, and ARAY and these free reports are accessible by registering at: http://www.aaaresearchreports.com/register/ On Thursday, shares in ZIOPHARM Oncology Inc. surged, as the broader market posted gains. The company's shares closed the day 4.26% higher at $3.67, after trading between $3.45 and $3.67. A total of 0.73 million shares were traded, which is below the daily average volume of 1.18 million. The company's shares have gained 2.23% in the previous three trading sessions and 22.74% in the last three months, outperforming the S&P 500, which has advanced 0.24% and 9.32% during the respective periods. Further, ZIOPHARM Oncology Inc.'s stock is trading above its 200-day moving average of $3.08. Sign up for free technical research on ZIOP at: http://www.AAAResearchReports.com/ZIOP112213.pdf Antares Pharma Inc.'s stock fluctuated between $3.80 and $3.93 before ending Thursday's session 2.63% higher at $3.90. A total of 0.92 million shares were traded, which is below the daily average volume of 1.73 million. The company's shares have gained 3.72% in the previous three trading sessions, outperforming the S&P 500, which has gained 0.24% during the same period. However, Antares Pharma Inc.'s stock is trading below its 50-day and 200-day moving averages of $4.12 and $4.02, respectively. Be sure to read our latest technical research on ATRS by registering at: http://www.AAAResearchReports.com/ATRS112213.pdf On Thursday, shares in Chelsea Therapeutics Intl. Ltd advanced to end the day at $3.38, which is 2.77% higher than the previous day's closing price of $3.29. The company's shares vacillated between $3.30 and $3.39 during the trading session. A total of 1.40 million shares were traded, which is above the daily average volume of 1.12 million. The company's shares have gained 15.39% in the last one month and 22.50% in the previous three months, outperforming the S&P 500, which has gained 2.93% and 9.32% during the respective periods. Moreover, Chelsea Therapeutics Intl. Ltd's stock is trading above its 50-day and 200-day moving averages of $3.01 and $2.40, respectively. Sign up and read the complimentary report on CHTP at: http://www.AAAResearchReports.com/CHTP112213.pdf Accuray Inc.'s stock advanced on Thursday, to end the day 2.09% higher at $8.29. The company's shares oscillated between $8.08 and $8.34 during the trading session. A total of 0.97 million shares were traded, which is below the daily average volume of 1.06 million. The company's shares have gained 7.24% in the last one month and 33.07% in the previous three months, outperforming the S&P 500, which has gained 2.93% and 9.32% during the respective periods. Additionally, Accuray Inc.'s stock is trading near its 52-week high of $8.48 and above its 50-day and 200-day moving averages of $7.33 and $5.80, respectively. The free report on ARAY can be downloaded by signing up now at: http://www.AAAResearchReports.com/ARAY112213.pdf ---- EDITOR NOTES: 1. This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5. For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. AAAresearchreports.com SOURCE AAA Research Reports Contact: Phone #: + 1 (646) 396-9126 Contact Name: Peter F. Jones Email ID: firstname.lastname@example.org